Antibody Drug Conjugates Market (5th Edition), 2019-2030

BEULAH, Colo. - July 27, 2020 - PRLog -- The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:

§  A detailed assessment of the current market landscape of ADCs.

§  Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.

§  An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.

§  A list of key opinion leaders (KOLs) within this domain.

§  An insightful competitiveness analysis of biological targets.

§  An analysis of the partnerships that have been established in the recent past.

§  An analysis of the investments made.

§

§  A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.

§  A case study on companies offering companion diagnostics.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of payload

§  MMAE

§  DM4

§  Camptothecin

§  AM1

§  MMAF

• Type of linker

§  VC

§  Sulfo-SPDB

§  SMCC

§  VA

§  Hydrazone linker

§  Others

• Target Indications

§  Breast Cancer

§  Lymphoma

§  Leukemia

§  Urothelial cancer

§  Lung cancer

§  Ovaria cancer

§  Others

• Target Antigen

§  CD30

§  HER2

§  CD22

§  CD33

§  Others

§  Small Molecule

• Technology Providers

§  Seattle Genetics

§  ImmunoGen

§  StemCentRx

§  Immunomedics

§  Others

• Key Geographies

§  North America

§  Europe

§  Asia Pacific

Key companies covered in the report (https://www.rootsanalysis.com/reports/view_document/antib...)

§  Bristol Myers Squibb

§  AbbVie

§  Astellas Pharma

§  AstraZeneca

§  Daiichi Sankyo

§  Pfizer

§  Roche / Genentech

§  Synthon

§  Bayer HealthCare

§  Biotest Pharmaceuticals

For more information please click on the following link:

https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html

Other Offerings

1.      ADC Contract Manufacturing Market (3rd Edition), 2018-2030 (https://www.rootsanalysis.com/reports/view_document/adc-c...)

2.      Gene Therapy Market (3rd Edition), 2019 - 2030 (https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html)

3.      Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 (https://www.rootsanalysis.com/reports/view_document/global-t-cell-car-t-tcr-and-til-therapy-market-4th-edition-2019--2030/261.html)

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com